Mission

Be a global reference in deeptech solutions by AI-driven innovation, transforming research and development, regulatory compliance and drug discovery actions in new and safer therapies to the patients.

AI-Powered Pharma

Be a strategic AI partner for pharmaceutical and biotech companies

Vision

Values

People and Collaboration

Ethics and Responsability

Knowledge and Innovation

Our services

At InsilicAll, we provide expert, tailored toxicology and advisory services to support the full lifecycle of your pharmaceutical products. Our dedicated team specializes in comprehensive non-clinical development, rigorous safety and risk assessments (including environmental, excipient, and impurity evaluations), and the precise derivation of safety exposure limits like PDE and OEL. We are committed to ensuring your compliance with global regulations, optimizing your drug development strategies, and accelerating your product's journey to market with safety and efficacy at the forefront. Partner with us for cost-effective, science-driven solutions tailored to your unique needs.

Nitrosamine Risk Assessment

Qualification of Non-Mutagenic Impurities

Potentially Mutagenic Impurities (PMIs)

Residual Solvents

Pharma Risk Assessment Services

Extractables & Leachables risk assessment

Qualification of Excipients

Elemental Impurities

In silico assessment

Permissible Daily Exposure (PDE) 

Health-Based Exposure Limits (HBELs) Services

Occupational Exposure Limits (OEL/OEB) 

Filling Data Gaps with Read-Across

Our products

Discover our suite of AI-driven software solutions, expertly designed to help you navigate regulatory compliance, manage critical risks, and accelerate innovation across the pharmaceutical, cosmetic, supplement, and food industries.

AI-Driven Industrial Pharmacoinformatics Solutions designed for compliance with FDA 21 CFR Part 11 and ANVISA's RDC No. 658/2021

Software solution providing end-to-end nitrosamine risk management for the Pharmaceutical, Cosmetic, Supplement, and Food industries

Software solution providing AI-driven mutagenicity and carcinogenicity assessment, boosted with RAx & expert review, ensuring ICH M7 & 21 CFR Part 11

Software solution providing AI-driven pKa and Ionization states, HPLC retention times, logP/D, solubility property prediction, boosted with hybrid Quantum Mechanical & AI models

Software solution providing a standardized, AI-driven approach for impurity risk assessment and ICH M7 purge factor calculations for API synthesis

Software solution providing generative AI & polypharmacology-driven molecular, biological signatures, creating multi-biological profiles, bridging chemistry and biology for drug discovery insights

Predict degradation products with Generative AI, grounded in reaction evidence, for ANVISA RDC 964/2025 & ICH compliant forced degradation studies

15

Dedicated Experts

300+

Successful R&D Projects

Trusted by

20+

Our Clients

Functioning as a Field Application Scientist and Regulatory Expert, he performs toxicological risk assessments during the pre-clinical and clinical development of drugs, cosmetics, environmental, and agricultural products. He also possesses experience in business management, securing public and private funds, and facilitating public-private Biotechnology partnerships within LATAM

Paulo H. M. Palmeira

Meet the team

Co-founder and CEO

Field Application Scientist

Dr. Rodolpho C. Braga

Co-founder and CTO

AI-driven drug discovery, Regulatory Expert

Leveraging over 15 years of computational modeling expertise, he spearheads the development of InsilicAll's Ecosystem software suite. It includes seven proprietary solutions for predictive toxicology and drug discovery, validated according to FDA 21 CFR Part 11 / GAMP5 guidelines to ensure suitability for use inside pharma companies. His technical leadership has propelled over 150 successful projects with major pharma clients, employing advanced techniques like Generative AI and atomic simulation

Dr. Ronaldo Pedro

Head of Innovation R&D

Dr. Fabricio Vargas

Co-founder

Scientist

He is the founder and Principal Investigator of NanoBusiness, a solid-state chemistry company operational in Brazil since 2008 with over 90 clients. NanoBusiness is uniquely ISO/IEC 17025 accredited and licensed by Anvisa/ICH for polymorphism analysis, utilizing its 20-person team, in-house PXRD equipment, and partnerships (SisNANO/MCTI). Recently arrived in the UK, the company's expansion is supported by the Department for International Trade (DIT)

Organic chemist with large experience as researcher and business management in the RD&I area at chemical and pharmaceutical industries. Vargas comes to InsilicAll as Head of Innovation to supervise the integration of InsilicAll's AI technology, foster innovation and ensure toxicological compliance for customers. Vargas will head an interdisciplinary group, support global projects, and boost corporate impacts. His inclusion promotes its aim to use AI to transform R&D and deliver innovative solutions for the industry